Immune-related adverse events from contemporary first-line combination therapies in metastatic renal cell carcinoma: Results from the IMDC

被引：0
|
作者：
Navani, V. [1 ]
Lemelin, A. [1 ]
Powles, T. B. [2 ]
Liow, E. C. H. [3 ]
Wong, S. S. L. [4 ]
Meza, L. A. [5 ]
Ebrahimi, H. [5 ]
Saliby, R. M. [6 ]
Saad, E. [6 ]
Yuasa, T. [7 ]
Wood, L. A. [8 ]
Kollmannsberger, C. K. [9 ]
Graham, J. [10 ]
North, S. [11 ]
Basappa, N. S. [11 ]
Donskov, F. [12 ]
Suarez Rodriguez, C. [13 ]
Lalani, A-K. [14 ]
Choueiri, T. K. [6 ]
Heng, D. Y. C. [1 ]
机构：
[1] Tom Baker Canc Clin, Med Oncol Dept, Calgary, AB, Canada
[2] Barts Hlth NHS Trust, Oncol Dept, St Bartholomews Hosp, London, England
[3] Monash Hlth, Med Oncol, Monash Med Ctr, Clayton, Vic, Australia
[4] Western Hlth, Med Affairs Dept, Sunshine Hosp, St Albans, Vic, Australia
[5] City Hope Comprehens Canc Ctr, Med Oncol, Duarte, CA USA
[6] Dana Farber Canc Inst, Med Oncol Dept, Boston, MA USA
[7] JFCR, Urol, Canc Inst Hosp, Koto Ku, Tokyo, Japan
[8] Dalhousie Univ, Div Med Oncol, Dept Med, Halifax, NS, Canada
[9] BC Canc Agcy Vancouver, Med Oncol Dept, Vancouver, BC, Canada
[10] Univ Manitoba, Med Oncol Dept, Fac Med Internal Med, Winnipeg, MB, Canada
[11] Univ Alberta, Med Oncol Dept, Cross Canc Inst, Edmonton, AB, Canada
[12] Aarhus Univ Hosp, Oncol Dept, Aarhus, Denmark
[13] Vall dHebron Univ Hosp, Oncol Dept, Barcelona, Spain
[14] Hamilton Hlth Sci, Genitourinary Oncol Dept, JCC Juravinski Canc Ctr, Med Oncol Div, Hamilton, ON, Canada
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1123
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1893P
引用
收藏
页码：S1018 / S1019
页数：2
相关论文
共 50 条
  • [41] Combination Therapy as First-Line Treatment in Metastatic Renal-Cell Carcinoma
    Escudier, Bernard
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (12): : 1176 - 1178
  • [42] Prognostic Impact of Early Treatment Interruption of Nivolumab Plus Ipilimumab Due to Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma: A Multi-Institution Retrospective Study
    Hiroki Ishihara
    Yuki Nemoto
    Kazutaka Nakamura
    Takashi Ikeda
    Hidekazu Tachibana
    Hironori Fukuda
    Kazuhiko Yoshida
    Hirohito Kobayashi
    Junpei Iizuka
    Hiroaki Shimmura
    Yasunobu Hashimoto
    Toshio Takagi
    Hideki Ishida
    Tsunenori Kondo
    Kazunari Tanabe
    Targeted Oncology, 2021, 16 : 493 - 502
  • [43] Outcomes of patients with brain metastases from renal cell carcinoma treated with firstline therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
    Takemura, Kosuke
    Lemelin, Audreylie
    Ernst, Matthew Scott
    Wells, Connor
    Basappa, Naveen S.
    Szabados, Bernadett
    Powles, Thomas
    Davis, Ian D.
    Wood, Lori
    Kapoor, Anil
    Mckay, Rana R.
    Lee, Jae-Lyun
    Meza, Luis A.
    Pal, Sumanta Monty
    Donskov, Frede
    Yuasa, Takeshi
    Gebrael, Benoit Beuselinck Georges
    Choueiri, Toni K.
    Heng, Daniel Yick Chin
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [44] Prognostic Impact of Early Treatment Interruption of Nivolumab Plus Ipilimumab Due to Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma: A Multi-Institution Retrospective Study
    Ishihara, Hiroki
    Nemoto, Yuki
    Nakamura, Kazutaka
    Ikeda, Takashi
    Tachibana, Hidekazu
    Fukuda, Hironori
    Yoshida, Kazuhiko
    Kobayashi, Hirohito
    Iizuka, Junpei
    Shimmura, Hiroaki
    Hashimoto, Yasunobu
    Takagi, Toshio
    Ishida, Hideki
    Kondo, Tsunenori
    Tanabe, Kazunari
    TARGETED ONCOLOGY, 2021, 16 (04) : 493 - 502
  • [45] Association between immune-related adverse events and survival in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab
    Hayase, T.
    Washino, S.
    Shirotake, S.
    Inoue, M.
    Kagawa, M.
    Takeshita, H.
    Miura, Y.
    Hyodo, Y.
    Izumi, K.
    Kawakami, S.
    Saito, K.
    Kageyama, Y.
    Oyama, M.
    Miyagawa, T.
    ANNALS OF ONCOLOGY, 2022, 33 : S1488 - S1489
  • [46] Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma
    Atkins, Michael B.
    Tannir, Nizar M.
    CANCER TREATMENT REVIEWS, 2018, 70 : 127 - 137
  • [47] Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma receiving first-line combination immunotherapies: results from the International Metastatic Renal Cell Carcinoma Database Consortium
    Takemura, K.
    Yuasa, T.
    Lemelin, A.
    Ferrier, E.
    Wells, J. C.
    Saad, E.
    Saliby, R. M.
    Basappa, N. S.
    Wood, L. A.
    Jude, E.
    Pal, S. K.
    Donskov, F.
    Beuselinck, B.
    Szabados, B.
    Powles, T.
    McKay, R. R.
    Gebrael, G.
    Agarwal, N.
    Choueiri, T. K.
    Heng, D. Y. C.
    ESMO OPEN, 2024, 9 (07)
  • [48] First-line treatment of metastatic renal cell carcinoma
    Bruchbacher, Andreas
    Netsch, Christopher
    Gross, Andreas J. J.
    UROLOGIE, 2023, 62 (08): : 830 - 839
  • [49] Incidence and impact of immune combination therapies adverse events in advanced renal cell carcinoma patients
    Catalano, Martina
    Venturi, Giulia
    Salfi, Alessia
    Bloise, Francesco
    Paolieri, Federico
    Galli, Luca
    Sisani, Michele
    Doni, Laura
    Roviello, Giandomenico
    IMMUNOTHERAPY, 2025,
  • [50] First-line therapy for metastatic renal cell carcinoma
    Sawhney, Paramvir
    Suyanto, Suyanto
    Michael, Agnieszka
    Pandha, Hardev
    JOURNAL OF CLINICAL UROLOGY, 2024, 17 (02) : 190 - 200
12345